Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Saturday.

According to Zacks, “Ritter Pharmaceuticals, Inc. is involved in developing therapeutic products to treat inflammatory, gastrointestinal and metabolic diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which is under development for the reduction of symptoms associated with lactose intolerance. Ritter Pharmaceuticals, Inc. is headquartered in Los Angeles, California. “

Several other research firms have also weighed in on RTTR. Maxim Group restated a “hold” rating on shares of Ritter Pharmaceuticals in a report on Friday, August 4th. Chardan Capital decreased their price target on Ritter Pharmaceuticals from $3.50 to $1.50 and set a “buy” rating on the stock in a report on Tuesday, August 8th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Ritter Pharmaceuticals has a consensus rating of “Buy” and an average price target of $4.88.

Ritter Pharmaceuticals (NASDAQ:RTTR) opened at 0.54 on Friday. The company’s market cap is $7.97 million. The stock has a 50 day moving average of $0.56 and a 200 day moving average of $1.58. Ritter Pharmaceuticals has a one year low of $0.54 and a one year high of $3.75.

Ritter Pharmaceuticals (NASDAQ:RTTR) last issued its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.14). On average, analysts anticipate that Ritter Pharmaceuticals will post ($0.42) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This story was reported by American Banking News and is the sole property of of American Banking News. If you are reading this story on another site, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The original version of this story can be read at https://www.americanbankingnews.com/2017/09/16/ritter-pharmaceuticals-inc-rttr-rating-lowered-to-hold-at-zacks-investment-research.html.

An institutional investor recently raised its position in Ritter Pharmaceuticals stock. KCG Holdings Inc. raised its holdings in Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) by 259.0% during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 105,409 shares of the biotechnology company’s stock after acquiring an additional 76,046 shares during the quarter. KCG Holdings Inc. owned approximately 0.91% of Ritter Pharmaceuticals worth $150,000 as of its most recent filing with the Securities & Exchange Commission. 7.62% of the stock is currently owned by institutional investors and hedge funds.

Ritter Pharmaceuticals Company Profile

Ritter Pharmaceuticals, Inc develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health.

Get a free copy of the Zacks research report on Ritter Pharmaceuticals (RTTR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Ritter Pharmaceuticals (NASDAQ:RTTR)

Receive News & Ratings for Ritter Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.